Liraglutide vs Semaglutide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Liraglutide
Liraglutide is a once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analog approved for both type 2 diabetes (Victoza, 1.8mg) and chronic weight management (Saxenda, 3mg). It was the foundational GLP-1 agonist that established the class's cardiovascular benefits and set the stage for semaglutide and tirzepatide.
Full profileSemaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management. It is FDA-approved under the brand names Ozempic (diabetes) and Wegovy (weight loss) and has become one of the most widely discussed peptides in mainstream health conversations.
Full profile| Liraglutide | Semaglutide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | NN2211, Victoza, Saxenda | Ozempic, Wegovy, Rybelsus, GLP-1 agonist |
| Evidence | FDA-approved | FDA-approved |
| Dosing range | 0.6mg–3.0mg mg, Once daily subcutaneous injection | 0.25mg–2.4mg mg, once weekly (injectable); once daily (oral Rybelsus) |
| Administration | Subcutaneous injection (abdomen, thigh, or upper arm) | Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus) |
| Key side effects | Nausea (most common, especially during initiation), Vomiting, Diarrhea, Decreased appetite | Nausea (very common, especially during dose escalation), Vomiting, Diarrhea or constipation, Reduced appetite (intended effect) |
| Cited sources | 2 references | 4 references |
Key differences
- Administration: Liraglutide — Subcutaneous injection (abdomen, thigh, or upper arm); Semaglutide — Subcutaneous injection (weekly — Ozempic/Wegovy), Oral tablet (daily — Rybelsus).
- Frequency: Liraglutide is typically Once daily subcutaneous injection; Semaglutide is once weekly (injectable); once daily (oral Rybelsus).
- Research depth: this profile cites 2 sources for Liraglutide vs 4 for Semaglutide.
How each works
Liraglutide
The LEADER trial (N=9340) demonstrated significant reduction in major adverse cardiovascular events (MACE) in high-risk T2D patients — the first cardiovascular outcomes trial for a GLP-1 agonist. The SCALE trials showed 5–8% mean weight loss at 3mg/day vs placebo. While superseded by semaglutide and tirzepatide in weight loss efficacy, liraglutide has the longest safety record in the class (approved 2010) and daily dosing allows finer tolerability titration.
Semaglutide
Semaglutide has robust clinical trial data — including the STEP and SUSTAIN trial series — demonstrating significant weight loss (15–20% body weight), glycemic control, and cardiovascular risk reduction. It works by mimicking the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, and reducing appetite via central nervous system signaling.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.